No, semaglutide is FDA-approved only for subcutaneous injection and is not formulated or studied for intravenous use
Research focus: metabolic health, obesity models, and cellular energy dynamics
10.1073/pnas.84.10.3434 36 DuH.GuoL.YanS.SosunovA
If dizziness prevents safe dose escalation, your provider may recommend a slower titration schedule, dose reduction, or a different peptide compound better suited to your individual tolerance profile
Additionally, Ozempic with alcohol deserves special consideration as it can: Affect blood sugar levels unpredictably Lead to poor food choices Potentially interfere with weight loss goals Increase the risk of gastrointestinal side effects While these foods should be limited, patients don't need to eliminate them completely
Clinical trials suggest that, on average, by week 12, a weight loss of at least 5% of the starting body weight is typically achievable